Key facts
- This page summarizes Brian J. Blaser's Form 4 filing for Talis Biomedical Corp.
- 2 reported transactions and 2 derivative rows are listed below.
- Accepted by SEC: 02 Dec 2021, 16:04.
Brian J. Blaser - 01 Dec 2021 Form 4 Insider Report for Talis Biomedical Corp
- Reporting relationship
- President and CEO, Director
- Issuer ticker
- N/A
- Reported as of
- 01 Dec 2021
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 02 Dec 2021, 16:04:39 UTC
- Prior SEC filing
- 20 Oct 2021
- Next SEC filing
- 25 Mar 2022
- Source filing
- View source filing
- Reporting owner signature
- /s/ J. Roger Moody, Jr., Attorney-in-Fact for Brian Blaser
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Brian J. Blaser filed Form 4 for Talis Biomedical Corp on 02 Dec 2021.
Change
- Previous filing in this sequence was filed on 20 Oct 2021.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
TLIS
transaction
Derivative
Stock Option (right to buy)
Award
- Transaction value
- $0
- Shares
- +750,000
- Change %
- Price
- $0.000000
- Shares after
- 750,000
- Date
- 01 Dec 2021
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 750,000
- Exercise price
- $4.47
- Footnotes
- F1
TLIS
transaction
Derivative
Restricted Stock Units
Award
- Transaction value
- $0
- Shares
- +625,000
- Change %
- Price
- $0.000000
- Shares after
- 625,000
- Date
- 01 Dec 2021
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 625,000
- Exercise price
- Footnotes
- F2, F3
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 3 footnotes
Footnote F1
20% of the shares underlying this option shall vest on the first annual anniversary of the vesting commencement date and 1/60th of the shares underlying this option shall vest monthly thereafter over 48 months.
Footnote F2
Each restricted stock unit represents a contingent right to receive one share of the Company's common stock upon vesting.
Footnote F3
20% of the shares shall vest on the first annual anniversary of the vesting commencement date and the balance of the shares will vest in a series of four equal successive annual installments.